TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?

Richard J RebelloChristoph Oing Silke Gillessen SommerRobert G Bristow

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.

Keyphrases

circulating tumor
cell free
circulating tumor cells
squamous cell carcinoma
small cell lung cancer
single cell
high throughput
cell therapy
combination therapy
single molecule
replacement therapy
smoking cessation